Darbufelone, a novel anti-infammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 2, 2010, Pages 277-285

  Ye, Xiaolei ^a   Zhou, Wu ^b   Li, Yongqi ^a   Sun, Yihua ^c   Zhang, Yihua ^a   Ji, Hui ^a   Lai, Yisheng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Anti infammatory drug; Arachidonic acid; Darbufelone; Lung cancer

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; DARBUFELONE; NEW DRUG; PROTEIN P27; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1B; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZOLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL NUCLEUS; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; ULTRASTRUCTURE; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASE 8; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINES;

EID: 77953052511     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1161-z     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Nishizawa Y, Yamasaki M, Katayama H, Amakata Y, Fushiki S (2007) Establishment of a progesterone-sensitive cell line from human lung cancer. Oncol Rep 18:685-690
3. Levine L (1981) Arachidonic acid transformation and tumor production. Adv Cancer Res 35:49-79
4. McGiff JC (1987) Arachidonic acid metabolism. Prev Med 16:503-509
5. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T (1999) Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5:1001-1005
6. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58:3761-3764
7. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A (1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997-5001
8. Abou-Issa H, Alshafie G (2004) Celecoxib: a novel treatment for lung cancer. Expert Rev Anticancer Ther 4:725-734
9. Rioux N, Castonguay A (1998) Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 19:1393-1400
10. Martin L, Rabasseda J, Castañer J (1999) Darbufelone mesilate- PD-136095-0073-CI-1004-antiarthritic-5-lipoxygenase inhibitor-COX-2 inhibitor. Drugs Future 24:853-857
11. Bannwarth B (2004) Is licofelone, a dual inhibitor of cyclo-oxygenase and 5-lipoxygenase, a promising alternative in anti-infammatory therapy? Fundam Clin Pharmacol 18:125-130
12. Xu XL, Chen XJ, Ji H, Li P, Bian YY, Yang D, Xu JD, Bian ZP, Zhang JN (2008) Astragaloside IV improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase. Pharmacology 81:325-332
13. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300
14. Britton MC (2000) American College of Rheumatology-63rd Annual Meeting. 13-17 November 1999, Boston, MA, USA. IDrugs 3:265-267
15. Rothschild B (2000) American College of Rheumatology-63rd annual meeting. 13-17 November 1999, Boston, MA, USA. IDrugs 3:158-163
16. Ling YH, Li T, Yuan Z, Haigentz M Jr, Weber TK, Perez-Soler R (2007) Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 72:248-258
17. Hung WC, Chang HC, Pan MR, Lee TH, Chuang LY (2000) Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol Pharmacol 58:1398-1403
18. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM (2008) Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66:208-217
19. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase- 2 inhibitors. Cancer Res 60:1306-1311
20. Skopinska-Rozewska E, Piazza GA, Sommer E, Pamukcu R, Barcz E, Filewska M, Kupis W, Caban R, Rudzinski P, Bogdan J, Mlekodaj S, Sikorska E (1998) Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): a potential mechanism for their antineoplastic properties. Int J Tissue React 20:85-89
21. Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A (2006) The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 6:9 22.
22. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ (2008) Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib+chemotherapy-cancer and leukemia group B trial 30203. J Clin Oncol 26:848-855